CBMT-26. HIGH MOBILITY GROUP AT-HOOK 2 (HMGA2) IS A PROGNOSTIC FACTOR ASSOCIATED WITH MALIGNANT PHENOTYPE IN MEDULLOBLASTOMAS. (5th November 2018)

• Record Type: Journal Article
• Authors: Arakawa, Yoshiki; Bin, Liu; Tanji, Masahiro; Mineharu, Yohei; Miyamoto, Susumu
• Is Part Of: Neuro-oncology. Volume 20(2018)Supplement 6
• Page Start: vi38
• Page End: vi38
• Publication Date: 2018-11-05
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noy148.145
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Medulloblastoma is an embryonal tumor arising in the cerebellum and its molecular mechanism has been revealed to be classified in several groups. The constitutive expression of high mobility group AT-hook 2 (HMGA2) is associated with malignant phenotype and reduced survival in some cancers. However, the clinical and biological significances of HMGA2 in medulloblastoma have not been elucidated. Here, we examined the expression, prognostic and therapeutic role of HMGA2 in medulloblastoma. HMGA1 and HMGA2 expressions were examined in 20 patients with medulloblastoma using immunohistochemical study. High expression levels of HMGA1 and HMGA2 were frequently identified in medulloblastoma tissues. In addition, high expression of HMGA2 correlated with high proliferation marker Ki-67 labeling index. High expression of HMGA2 was significantly associated with progression free survival and overall survival of patients with medulloblastoma (p=0.021 and p=0.016, respectively). To examine the function of HMGA2 expression, knock-down HMGA2 expression was applied in Daoy, D283 and D341 cells. Knock-down of HMGA2 resulted in inhibited cell proliferation, migration/invasion and enhanced apoptosis in vitro. In conclusion, HMGA2 overexpression is frequent in medulloblastoma, and its expression is related to proliferation marker and poor prognosis. These findings suggest that HMGA2 could serve as a potential target for future therapeutic strategies in medulloblastoma.